AU1951001A - Microbial delivery system - Google Patents

Microbial delivery system

Info

Publication number
AU1951001A
AU1951001A AU1951001A AU1951001A AU1951001A AU 1951001 A AU1951001 A AU 1951001A AU 1951001 A AU1951001 A AU 1951001A AU 1951001 A AU1951001 A AU 1951001A AU 1951001 A AU1951001 A AU 1951001A
Authority
AU
Australia
Prior art keywords
proteins
allergic
allergens
subjects
microorganisms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU1951001A
Other languages
English (en)
Inventor
Michael Caplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seer Pharmaceuticals LLC
Original Assignee
Panacea Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Pharmaceuticals LLC filed Critical Panacea Pharmaceuticals LLC
Publication of AU1951001A publication Critical patent/AU1951001A/xx
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU1951001A 2000-04-06 2000-12-06 Microbial delivery system Pending AU1951001A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19503500P 2000-04-06 2000-04-06
US09/731,375 US8153414B2 (en) 2000-04-06 2000-12-06 Microbial delivery system
PCT/US2000/033121 WO2001066136A2 (en) 2000-04-06 2000-12-06 Microbial delivery system

Publications (1)

Publication Number Publication Date
AU1951001A true AU1951001A (en) 2001-09-17

Family

ID=26890647

Family Applications (2)

Application Number Title Priority Date Filing Date
AU1951001A Pending AU1951001A (en) 2000-04-06 2000-12-06 Microbial delivery system
AU2001219510A Ceased AU2001219510B2 (en) 2000-04-06 2000-12-06 Microbial delivery system

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001219510A Ceased AU2001219510B2 (en) 2000-04-06 2000-12-06 Microbial delivery system

Country Status (11)

Country Link
US (6) US8153414B2 (enExample)
EP (1) EP1272213B1 (enExample)
JP (3) JP2004527450A (enExample)
AT (1) ATE319475T1 (enExample)
AU (2) AU1951001A (enExample)
CA (1) CA2403292C (enExample)
CY (1) CY1105216T1 (enExample)
DE (1) DE60026584T2 (enExample)
DK (1) DK1272213T3 (enExample)
ES (1) ES2260078T3 (enExample)
WO (1) WO2001066136A2 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6698162B2 (en) * 2000-03-23 2004-03-02 Teikoku Pharma Usa, Inc. Methods of producing a terminally sterilized topical patch preparation
AU1951001A (en) * 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
EP1278550A4 (en) * 2000-04-07 2004-05-12 Univ California SYNERGISTIC IMPROVEMENTS OF POLYNUCLEOTIDE VACCINE
US7083787B2 (en) * 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
US7060687B2 (en) 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
CA2508957C (en) * 2002-12-16 2015-11-17 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20070231796A1 (en) 2003-09-17 2007-10-04 The Regents Of The University Of California Sensor and method for detection of a target substance
JP5234445B2 (ja) * 2004-10-05 2013-07-10 源一郎 杣 薬剤
BRPI0516356A (pt) * 2004-10-18 2008-09-02 Globeimmune Inc terapia à base de levedura para infecções crÈnicas da hepatite c
JP2009500454A (ja) * 2005-07-11 2009-01-08 グローブイミューン， インコーポレイテッド 標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
WO2007133835A2 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and mehods related thereto
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
CN104120086A (zh) * 2007-02-02 2014-10-29 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) * 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US9402896B2 (en) 2008-02-01 2016-08-02 Murdoch Childrens Research Institute Method of inducing tolerance to an allergen
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
KR101781966B1 (ko) 2009-04-17 2017-09-27 글로브이뮨 암에 대한 병용 면역요법 조성물 및 방법
JP2012532933A (ja) * 2009-07-13 2012-12-20 ヴァックスジーン コーポレーション 食用微生物を使用して生産し投与される経口ワクチン
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2012083302A2 (en) 2010-12-17 2012-06-21 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
AU2012214394B2 (en) 2011-02-12 2016-08-11 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis B infection
PL2685995T3 (pl) 2011-03-17 2017-10-31 Globeimmune Inc Kompozycje immunoterapeutyczne drożdże-Brachyury
SG10201605265TA (en) 2011-06-14 2016-08-30 Globeimmune Inc Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection
CA2844500C (en) 2011-08-17 2022-05-10 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
US20130216589A1 (en) * 2012-02-17 2013-08-22 Rich Content Biotech INC. Oral vaccine for aquatic animals
EP2841098A4 (en) 2012-04-23 2016-03-02 Allertein Therapeutics Llc NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
HK1209835A1 (en) 2012-06-26 2016-04-08 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
WO2014049604A2 (en) * 2012-09-05 2014-04-03 Amrita Therapeutics Limited A novel biomedical device for cancer therapy
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
EP2968529B1 (en) 2013-03-14 2020-08-05 Aimmune Therapeutics, Inc. Manufacture of peanut formulations for oral desensitization
EP2976100B1 (en) 2013-03-19 2020-07-01 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP3760223A1 (en) 2013-04-03 2021-01-06 N-Fold Llc Nanoparticle composition for desensitizing a subject to peanut allergens
TWI654200B (zh) 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
US11215615B2 (en) 2014-04-03 2022-01-04 AllerGenis LLC Peptides, reagents and methods for detecting food allergy
EP3129036B1 (en) 2014-04-11 2021-08-11 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI748957B (zh) 2015-08-03 2021-12-11 美商環球免疫公司 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN118949022A (zh) * 2017-10-25 2024-11-15 阿莱罗治疗私人有限公司 通过施用抗原特异性配制品治疗免疫性疾病
EP3703743A4 (en) 2017-11-02 2021-12-08 Aimmune Therapeutics, Inc. ORAL IMMUNOTHERAPY PROCEDURES
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
EP3836801A4 (en) 2018-08-16 2022-05-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401214B2 (en) 2018-12-20 2025-09-04 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
US11229673B2 (en) 2019-05-10 2022-01-25 Société des Produits Nestlé S.A. Methods for improving the quality of life of a patient with a peanut allergy
EP4100057A4 (en) * 2020-02-06 2024-02-21 Allergenis LLC ASSAYS FOR DETECTION OF PEANUT ALLERGIES
WO2025212530A1 (en) 2024-04-01 2025-10-09 N-Fold Llc Nanoparticle manufacturing

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US588799A (en) * 1897-08-24 Mechanism
US3097141A (en) 1959-02-26 1963-07-09 Kidwell Elizabeth N Wilcox Immunological method
SE337223B (enExample) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4171299A (en) 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4338297A (en) 1980-02-19 1982-07-06 Michael Jacob G Polypeptide active pollen immunosuppressant fraction
US4469677A (en) 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
EP0063810B1 (en) 1981-04-29 1986-03-05 Ciba-Geigy Ag New devices and kits for immunological analysis
CA1338705C (en) * 1981-10-22 1996-11-12 Roy Curtiss Iii Vaccines obtained from antigenic gene products of recombinant genes
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
SE8205908D0 (sv) 1982-10-18 1982-10-18 Pharmacia Diagnostics Ab Sett att bilda polymerskikt
US4849337A (en) 1983-01-31 1989-07-18 Minnesota Mining And Manufacturing Company Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody
CA1260828A (en) 1983-07-04 1989-09-26 Masakazu Iwai Therapeutic and prophylactic agent for gastrointestinal ulcers
US4579840A (en) 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4680174A (en) 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4696915A (en) 1984-05-25 1987-09-29 Hoffmann-La Roche Inc. Parathymosin alpha
US5026545A (en) 1984-09-17 1991-06-25 Baxter International, Inc. Treatment of allergy and composition therefor
US4658022A (en) 1985-08-08 1987-04-14 Molecular Diagnostics, Inc. Binding of antibody reagents to denatured protein analytes
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US4900556A (en) 1985-04-26 1990-02-13 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5843710A (en) 1987-07-07 1998-12-01 Biotech Australia Pty. Limited And Csiro Vaccines against animal parasitic nematodes
US5049390A (en) 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
AT393137B (de) 1988-10-14 1991-08-26 Biomay Biotech Prod Verfahren zum screenen einer expressions-cdna- klonbank zur auffindung von polynukleotiden
US5061790A (en) 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
JP2787162B2 (ja) 1989-08-24 1998-08-13 フマキラー株式会社 精製ダニアレルゲン
US5834246A (en) * 1989-09-18 1998-11-10 Vitec Aktiebolag Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
DK0500785T3 (da) 1989-11-03 2002-08-19 Immulogic Pharma Corp Humant T-celleaktivitet felint protein (TRFP) isoleret fra husstøv samt anvendelser heraf
US6019972A (en) 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5328991A (en) 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US5747641A (en) 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
EP0514458A1 (en) 1990-01-31 1992-11-25 The Board of Regents for the University of Oklahoma Assays and treatments for autoimmune diseases
US6897287B1 (en) 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5091318A (en) 1990-04-13 1992-02-25 Abbott Laboratories Binding of allergens to a solid phase
US5888762A (en) 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
EP0495052A1 (en) 1990-08-08 1992-07-22 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Allergens of alder pollen and applications thereof
CA2067182A1 (en) 1990-08-13 1992-02-14 Rudolf Valenta Birch pollen allergen p14 for diagnosis and therapy of allergic diseases
AT401180B (de) 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
JP3139777B2 (ja) 1990-08-27 2001-03-05 フマキラー株式会社 組換えダニアレルゲン
DE69130760T2 (de) 1990-09-17 1999-07-22 Mitsui Chemicals, Inc., Tokio/Tokyo Polycarbonate, ihre verwendung, herstellung und reinigung
US5599537A (en) 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US5219990A (en) 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
US5350835A (en) 1991-11-05 1994-09-27 Board Of Regents, University Of Texas Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
JP3156237B2 (ja) 1991-12-24 2001-04-16 雪印乳業株式会社 抗ヒトＩｇＥ モノクローナル抗体
GB2278358B (en) * 1992-02-27 1995-07-26 Lynxvale Ltd Heterologous gene expression in Lactococcus,and the expression products therefrom
US5480972A (en) 1992-10-30 1996-01-02 The University Of Melbourne Allergenic proteins from Johnson grass pollen
SG52402A1 (en) 1992-12-22 1998-09-28 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins
US5558869A (en) 1992-12-30 1996-09-24 University Of Arkansas Major peanut allergen ara h II
US5939283A (en) 1992-12-31 1999-08-17 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
ES2114184T3 (es) 1993-02-12 1998-05-16 Mayo Foundation Composicion a base de microparticulas en fase condensada y procedimiento.
DE69434951D1 (de) 1993-02-22 2007-05-24 Gen Hospital Corp Heterologe antigene in stämmen zur impfung mit lebendzellen
JP3451572B2 (ja) 1993-03-04 2003-09-29 アサヒビール株式会社 改変したダニ主要アレルゲン及びその製造方法
WO1994021675A2 (en) 1993-03-12 1994-09-29 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US5710126A (en) 1993-03-12 1998-01-20 Immulogic Pharmaceutical Corporation T cell epitopes of ryegrass pollen allergen
US6849427B1 (en) 1993-03-12 2005-02-01 Immulogic Pharmaceutical Corp. Nucleic acids encoding a house dust mite allergen, Der p VII, and uses therefor
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JP3350794B2 (ja) 1993-09-29 2002-11-25 アサヒビール株式会社 改変したダニ主要アレルゲン
JP2828391B2 (ja) 1993-10-29 1998-11-25 東燃株式会社 オリゴ糖を表面に有するリポソーム
US5449669A (en) 1993-11-10 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services IgE-binding epitopes of a major heat-stable crustacean allergen derived from shrimp
US5731157A (en) 1993-12-30 1998-03-24 The Procter And Gamble Company Two-site allergen immunoassay
US5820862A (en) 1994-04-14 1998-10-13 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
JPH07285875A (ja) 1994-04-19 1995-10-31 Mineo Hayazaki ノミアレルゲンの製造方法および該方法により製造されるノミアレルゲン
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
SE9402089D0 (sv) 1994-06-14 1994-06-14 Rudolf Valenta Recombinant allergen, fragments thereof, corresponding recombinant DNA molecules, vectors and hosts containing the DNA molecules, diagnostic and therapeutic uses of said allergens and fragments
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6187311B1 (en) * 1995-03-28 2001-02-13 Asahi Breweries, Ltd. Engineered acarid allergen and process for producing the same
US5773003A (en) 1995-03-31 1998-06-30 Immulogic, Inc. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5869040A (en) 1995-06-07 1999-02-09 Biogen, Inc Gene therapy methods and compositions
US5820880A (en) 1995-06-07 1998-10-13 The United States Of America As Represented By The Secretary Of The Army Liposomal formulation
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
WO1997024139A1 (en) 1995-12-29 1997-07-10 University Of Arkansas Peanut allergens and methods
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
SE9604815D0 (sv) * 1996-12-20 1996-12-20 Pharmacia & Upjohn Ab A metod of diagnosis
BR9808441A (pt) * 1997-03-28 2000-05-23 Cytoclonal Pharmaceutics Inc Composição farmacêutica para administração a um animal, vetor transportador, vetores para transportar e expressar genes selecionados em escherichia coli e de uma cepa de mycobacterium, processo para administrar a um animal uma quantidade eficaz da composição farmacêutica, e, meio de cultura.
US5989814A (en) 1997-04-01 1999-11-23 Reagents Of The University Of California Screening methods in eucaryotic cells
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
EP0877033B1 (en) 1997-05-08 2007-09-12 Amarnath Maitra A process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
DE19729327C1 (de) * 1997-07-09 1998-10-29 Wieland Electric Gmbh Schutzleiterklemme
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
DE69940805D1 (de) * 1998-01-31 2009-06-10 Sinai School Medicine Verfahren und reagenzien zur verminderung der klinischen reaktion zur allergie
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6270723B1 (en) 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
CA2333750A1 (en) * 1998-06-23 1999-12-29 Dale T. Umetsu Adjuvant therapy
US6004815A (en) * 1998-08-13 1999-12-21 The Regents Of The University Of California Bacteria expressing nonsecreted cytolysin as intracellular microbial delivery vehicles to eukaryotic cells
JP2000210050A (ja) 1998-11-20 2000-08-02 Asama Kasei Kk 免疫調節活性分解物およびその製造方法並びにそれを用いた食品
WO2000054803A2 (en) * 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
AU1951001A (en) * 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
DK1219300T3 (da) 2000-12-28 2007-03-05 Biomay Prod & Handel Behandling af allergi
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
CY1105216T1 (el) 2010-03-03
EP1272213B1 (en) 2006-03-08
CA2403292C (en) 2011-02-08
US8153414B2 (en) 2012-04-10
JP2004527450A (ja) 2004-09-09
WO2001066136A2 (en) 2001-09-13
JP2009242427A (ja) 2009-10-22
US20040208894A1 (en) 2004-10-21
ATE319475T1 (de) 2006-03-15
DK1272213T3 (da) 2006-07-10
JP2012207032A (ja) 2012-10-25
DE60026584T2 (de) 2007-03-08
US20130243814A1 (en) 2013-09-19
AU2001219510B2 (en) 2007-06-14
CA2403292A1 (en) 2001-09-13
US20030035810A1 (en) 2003-02-20
EP1272213A2 (en) 2003-01-08
ES2260078T3 (es) 2006-11-01
WO2001066136A3 (en) 2001-12-27
US8815251B2 (en) 2014-08-26
US20040234548A1 (en) 2004-11-25
US20130142817A1 (en) 2013-06-06
DE60026584D1 (de) 2006-05-04
US20110027298A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
AU1951001A (en) Microbial delivery system
Ryan et al. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens
CY1110727T1 (el) Παρασκευασματα θετικων κατα gram βακτηριων για τη θεραπεια ασθενειων που περιλαμβανουν μια ανοσολογικη δυσρυθμιση
WO2004087203A3 (en) Immunostimulatory nucleic acid oil-in-water formulations for topical application
Tang et al. Oral immunotherapy and tolerance induction in childhood
WO2003061578A3 (en) Compositions for treatment or prevention of bioterrorism
WO2003061558A3 (en) Glycoconjugate vaccines for use in immune-compromised populations
WO2000054803A3 (en) Immunostimulatory nucleic acids and antigens
EP1243274A3 (en) Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
WO2003055513A3 (en) Bacillus subtilis spores to stimulate the immune responses
Pfaar et al. Ultra‐short‐course booster is effective in recurrent grass pollen‐induced allergic rhinoconjunctivitis
WO2007044406A3 (en) Methods for stimulating an immune response using bacterial antigen delivery system
Sharquie BCG is a good immunotherapeutic agent for viral and autoimmune diseases: is it a new weapon against coronavirus (COVID-19)?
TR200001948T2 (tr) Mikobakteri vaccaesinden türetilen kompozisyonlar ve bunların kullanımları için metotlar.
EP4295862A3 (en) Coronavirus vaccine
WO2002034287A3 (en) Therapeutic vaccine formulations containing chitosan
EP2174665A3 (en) Compositions and methods for activating innate and allergic immunity
Pichler et al. The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model
Sánchez-Ramón et al. Extending the clinical horizons of mucosal bacterial vaccines: current evidence and future prospects
Kim et al. Infection, allergy and the hygiene hypothesis: historical perspective
WO2001049319A8 (de) Zusammensetzung, enthaltend bakterielle antigene, zum vorbeugen und behandeln von allergischen erkrankungen
Trujillo et al. Inhibition of allergic disorders by infection with bacteria or the exposure to bacterial products
DE60109180D1 (de) Parietaria judaica ns-ltp-antigenvarianten, entsprechende pharmazeutische zusammensetzungen und ihre verwendung
EP1262491A3 (en) Non-anaphylactogenic IgE vaccines
Grüber et al. Common vaccine antigens inhibit allergen‐induced sensitization and airway hyperresponsiveness in a murine model